AU2022357634A1 - Binding agents targeting trop2-expressing tumor cells - Google Patents

Binding agents targeting trop2-expressing tumor cells Download PDF

Info

Publication number
AU2022357634A1
AU2022357634A1 AU2022357634A AU2022357634A AU2022357634A1 AU 2022357634 A1 AU2022357634 A1 AU 2022357634A1 AU 2022357634 A AU2022357634 A AU 2022357634A AU 2022357634 A AU2022357634 A AU 2022357634A AU 2022357634 A1 AU2022357634 A1 AU 2022357634A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
set forth
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022357634A
Other languages
English (en)
Inventor
Luis DA CRUZ
Wenyang HOU
Shugang YAO
David S. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kisoji Biotechnology Inc
Original Assignee
Kisoji Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kisoji Biotechnology Inc filed Critical Kisoji Biotechnology Inc
Publication of AU2022357634A1 publication Critical patent/AU2022357634A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022357634A 2021-09-29 2022-09-28 Binding agents targeting trop2-expressing tumor cells Pending AU2022357634A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163249728P 2021-09-29 2021-09-29
US63/249,728 2021-09-29
US202263326572P 2022-04-01 2022-04-01
US63/326,572 2022-04-01
PCT/CA2022/051437 WO2023049999A1 (en) 2021-09-29 2022-09-28 Binding agents targeting trop2-expressing tumor cells

Publications (1)

Publication Number Publication Date
AU2022357634A1 true AU2022357634A1 (en) 2024-05-09

Family

ID=85780298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022357634A Pending AU2022357634A1 (en) 2021-09-29 2022-09-28 Binding agents targeting trop2-expressing tumor cells

Country Status (10)

Country Link
US (4) US20240360242A1 (https=)
EP (1) EP4408893A4 (https=)
JP (1) JP2024535930A (https=)
KR (1) KR20240082383A (https=)
AU (1) AU2022357634A1 (https=)
CA (1) CA3231574A1 (https=)
IL (1) IL311673A (https=)
MX (1) MX2024003779A (https=)
TW (1) TW202330605A (https=)
WO (1) WO2023049999A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4408893A4 (en) 2021-09-29 2026-02-18 Kisoji Biotechnology Inc Binding agents targeting tumor cells expressing too much 2
CN121419995A (zh) * 2023-04-04 2026-01-27 加拿大商木曾路生物科技公司 靶向表达trop2的肿瘤细胞的结合剂
WO2024051383A1 (zh) * 2023-07-28 2024-03-14 上海洛启生物医药技术有限公司 抗Trop2抗体、包含所述抗体的缀合物及其应用
WO2026059880A1 (en) * 2024-09-12 2026-03-19 Modernatx, Inc. Trop2 binding molecules, nucleic acids encoding same, and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
EP3600283A4 (en) * 2017-03-27 2020-12-16 Immunomedics, Inc. TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
GB201811368D0 (en) * 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN112646038B (zh) * 2019-10-11 2025-06-03 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用
EP4077374A4 (en) 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME
CN113527496B (zh) * 2020-04-16 2022-03-04 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN112321715B (zh) * 2020-11-03 2022-05-10 博奥信生物技术（南京）有限公司 抗trop2纳米抗体及其制备方法和应用
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
EP4408893A4 (en) 2021-09-29 2026-02-18 Kisoji Biotechnology Inc Binding agents targeting tumor cells expressing too much 2

Also Published As

Publication number Publication date
US20240317886A1 (en) 2024-09-26
US20240327537A1 (en) 2024-10-03
TW202330605A (zh) 2023-08-01
MX2024003779A (es) 2024-04-19
EP4408893A1 (en) 2024-08-07
EP4408893A4 (en) 2026-02-18
IL311673A (en) 2024-05-01
US12371508B2 (en) 2025-07-29
US12338295B2 (en) 2025-06-24
US20240317887A1 (en) 2024-09-26
US20240360242A1 (en) 2024-10-31
US12275799B2 (en) 2025-04-15
WO2023049999A1 (en) 2023-04-06
KR20240082383A (ko) 2024-06-10
CA3231574A1 (en) 2023-04-06
JP2024535930A (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
US12338295B2 (en) Binding agents targeting TROP2-expressing tumor cells
AU2019356806B2 (en) Antibody constructs binding 4-1BB and tumor-associated antigens and uses thereof
US12415861B2 (en) Anti C-MET antibodies
US10836833B2 (en) Cell engaging binding molecules
EP4324853A1 (en) Multi-specific antibody targeting bcma
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CN111788229A (zh) Csf1r结合剂
KR20260007641A (ko) Trop2를 발현하는 종양 세포를 표적으로 하는 결합제
CN118159566A (zh) 靶向表达trop2的肿瘤细胞的结合剂
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2025242212A1 (en) Anti-sstr2 antibodies
HK40120932A (zh) 抗体及其药物偶联物和用途